Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Lance Bredvold who wrote (15894)	7/17/2002 12:29:47 PM
From: Cacaito	Read Replies (2) \| Respond to of 17367

Bpi retina program is conducted by the Joslin Institute in Boston, one of the worlds most respected institutions in the field. Bpi could end up being the most effective and less toxic product for macular degeneration. The animal and basic science studies are excellent. This alone is a very good reason to own xoma and the main reason I followed the company. Xanelim will sustain the price in the next 2 to 3 years, since is already bottom, it is a reasonable entrance at this point, and a reasonable hold.